Antares Pharma, Inc. (AIS) Reports In-Line Q3 EPS Loss of $0.01
Tweet
Share
E-mailGet Alerts AIS Hot Sheet
Price: $72.10 +1.38%
Financial Fact:
Total cost of revenue: 8.03M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total cost of revenue: 8.03M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Antares Pharma, Inc. (NYSE: AIS) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $3.85 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
- Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
